Robaxin Does Not Cause Hematuria
Robaxin (methocarbamol) is not associated with hematuria (blood in urine) based on FDA labeling and available evidence. The official FDA prescribing information for Robaxin does not list hematuria as a known adverse reaction 1.
What the FDA Drug Label Shows
The comprehensive adverse reaction profile for Robaxin includes:
- Body systems affected: Cardiovascular (bradycardia, hypotension), digestive (nausea, vomiting, jaundice), nervous system (dizziness, drowsiness, seizures), skin reactions (rash, urticaria), and hematologic effects (leukopenia) 1
- Notably absent: Hematuria or any urinary bleeding is not mentioned anywhere in the adverse reaction listings
The only urinary-related monitoring mentioned in overdose management is "monitoring urinary output" as part of supportive care, not because of bleeding risk 1.
Clinical Context
When evaluating a patient on Robaxin who presents with hematuria, you should:
Look elsewhere for the cause. The most common medication-related causes of hematuria are:
- Anticoagulants: Rivaroxaban and warfarin are the highest risk medications for hematuria 2
- Antiplatelet agents: Aspirin, clopidogrel 2
- Other high-risk drugs: Cyclophosphamide, NSAIDs like ibuprofen 2
Conduct proper hematuria evaluation per current guidelines 3, 4:
- Detailed history including smoking (pack-years), age, gender, occupational exposures
- Physical examination with blood pressure and serum creatinine
- Risk stratification using the AUA/SUFU 2025 criteria
- Consider cystoscopy for intermediate to high-risk patients
- Imaging (CT urography) as indicated by risk level
Common Pitfall to Avoid
Do not attribute hematuria to Robaxin simply because a patient is taking it. This medication has been in use since 1959 with extensive post-marketing surveillance, and hematuria has never emerged as a recognized adverse effect 1. Missing the actual cause—whether malignancy (bladder cancer risk 1.3-6.3% depending on risk factors), stones, infection, or other medications—could delay critical diagnosis and worsen outcomes 3.